Dyne Therapeutics (DYN) Net Income towards Common Stockholders (2019 - 2026)

Dyne Therapeutics (DYN) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$262.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 140.54% year-over-year to -$262.6 million; the TTM figure through Jun 2026 stood at -$657.2 million (down 53.32% YoY), while the FY2025 annual figure was -$857.6 million, down 41.6% from the prior year.
• Net Income towards Common Stockholders retreated to -$262.6 million in Q2 2026 per DYN's latest filing, from -$175.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$62.5 million in Q1 2022 and bottomed at -$262.6 million in Q2 2026.
• Historically, Net Income towards Common Stockholders has averaged -$131.2 million across 5 years, with a median of -$108.7 million in 2025.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 193.23% — and 2025, when it jumped 56.35%.
• Dyne Therapeutics' Net Income towards Common Stockholders stood at -$152.4 million in 2022, then sank by 38.9% to -$211.7 million in 2023, then soared by 55.37% to -$94.5 million in 2024, then fell by 17.48% to -$111.0 million in 2025, then slumped by 136.53% to -$262.6 million in 2026.
• Business Quant data shows DYN's Net Income towards Common Stockholders at -$262.6 million in Q2 2026, -$175.3 million in Q1 2026, and -$111.0 million in Q4 2025.